Dr. Nagourney's Blog


Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Victories in Acute Leukemia - Opportunities to Expand the Horizon
By Robert A. Nagourney, MD
The March 29, 2016 Wall Street Journal  reported a 23-year-old man with acute myeloid leukemia (AML). Using genomic (DNA) profiling a FLT3 (FMS-like tyrosine kinase-3) mutation was identified and Sorafenib, a drug that targets FLT-3, provided...
Seventh Time’s the Charm-Unexpected Response in Relapsed Leukemia
By Robert A. Nagourney, MD
For medical oncologists, the choice of chemotherapy drugs is one of statistical probability. For cancer patients, it is a...
With an EVA-PCD Assay, It Can Be That Simple - End Stage CLL Success
By Robert A. Nagourney, MD
Shortly after I left the university and joined a medical oncology group, one of the junior members of the practice asked if I...
Cure the Curable, Treat the Treatable and Avoid Futile Care
By Robert A. Nagourney, MD
During my interview with Jeff Michaels on the March 28, 5:00 P.M. Fox News, we explored the themes of my current book,...
Phar Lap and the Treatment of Leukemia
By Robert A. Nagourney, MD
Phar Lap (1926-1932) was a thoroughbred horse bred in New Zealand. After winning the Melbourne Cup and 37 other races, his...
A Tale of Two Trials - AML & Stage 3 Non Small Cell Lung Cancer
By Robert A. Nagourney, MD
As I read through the November 10 issue of the Journal of Clinical Oncology there were two very different but highly...
Stalking Leukemia Genes One Whole Genome at a Time
By Robert A. Nagourney, MD
An article by Gina Kolata on the front page of the July 8, Sunday New York Times, “In Leukemia Treatment, Glimpses of the...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.